Last update:
Immunology news
Oncology & Cancer
Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using the T-Charge platform, ...
41 minutes ago
0
0
Oncology & Cancer
Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
59 minutes ago
0
0
Home-based monitoring could transform care for patients receiving T-cell redirecting therapies
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows that these patients can ...
1 hour ago
0
0
New data highlight promise of pivekimab sunirine in two aggressive blood cancers
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive ...
1 hour ago
0
0
Rethinking long-term allergy treatments: Experimental vaccine protects against anaphylaxis in mice
Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E antibodies in humanized mice, protects against Immunoglobulin E-mediated anaphylaxis, and shows no detectable ...
'Ready-made' T-cell gene therapy tackles 'incurable' T-cell leukemia
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare ...
14 hours ago
0
8
Immunotherapy works for sepsis thanks to precision approach
Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient's immune system condition. While earlier research showed little benefit of immunotherapy in sepsis, a new study demonstrates ...
19 hours ago
0
2
A routine blood test could help predict who benefits most from CAR T-cell therapy
Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians ...
14 hours ago
0
0
CAR T cell therapy shows promising Phase II trial results in multiple myeloma
The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory multiple myeloma, according to new trial data from researchers at The ...
17 hours ago
0
0
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
20 hours ago
0
1
New combination approach aims to make CAR T more durable in lymphoma
A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.
14 hours ago
0
0
Milder chemotherapy proves effective for rare, aggressive lymphoma
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, ...
16 hours ago
0
0
Prognostic tool could help clinicians identify high-risk cancer patients
Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate. Patients often relapse after receiving initial therapy, making it especially challenging for clinicians to ...
14 hours ago
0
0
Hormonal fluctuations affect women's immunity, but a lack of rigor in studies still prevents a consensus
Hormonal fluctuations throughout a woman's life are among the factors that most influence the immune system. Like a seesaw, variations in estrogen and progesterone affect cellular levels and alter the immune and inflammatory ...
15 hours ago
0
0
Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma
New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, ...
17 hours ago
0
0
New antibody boosts immune response against blood cancers and solid cancers
In a recent preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as ...
17 hours ago
0
0
New trial shows early signs that 'off-the-shelf' CAR T-cell therapy could transform treatment of myeloma
Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T-cell therapy, which generates CAR T-cells inside the body, could offer a faster, easier and more ...
19 hours ago
0
0
Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially preventable
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high ...
20 hours ago
0
0
Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax ...
Dec 8, 2025
0
0
Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes
In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard ...
Dec 8, 2025
0
0
New findings support a chemo-free approach for treating Ph+ ALL
A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The Phase III trial, which included adult ...
Dec 8, 2025
0
0
Black patients with AML are younger at diagnosis, experience poorer survival outcomes than white patients, data show
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to ...
Dec 8, 2025
0
0
Trial shows chemotherapy and radiation are comparable as pre-transplant conditioning for patients with B-ALL
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning ...
Dec 8, 2025
0
0
Measurable residual disease shows strong potential as an early indicator of survival in patients with AML
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients ...
Dec 8, 2025
0
0
Altering the daily timing of immunotherapy could improve survival in people with cancer
Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a study published in Cancer.
Dec 8, 2025
0
0
